Molecular-driven treatment for biliary tract cancer: the promising turning point

References

• Berardi R, Scartozzi M, Freddari F, et al., Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review. Cancer Treat Rev. 2006;32(5):333–347.
   PubMed Web of Science ®Google Scholar
• Personeni N, Lleo A, Pressiani T, et al., Biliary tract cancers: molecular heterogeneity and new treatment options. Cancers (Basel). 2020;12(11):3370.
   Web of Science ®Google Scholar
• Lin J, Cao Y, Yang X, et al. Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics. 2021;11(10):4585–4598.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010.
   PubMed Web of Science ®Google Scholar
• Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154–4161.
   PubMed Web of Science ®Google Scholar
• Li M, Zhang Z, Li X, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46:872–876.
   PubMed Web of Science ®Google Scholar
• Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17(1):72–79.
   PubMed Web of Science ®Google Scholar
• Deshpande V, Nduaguba A, Zimmerman SM, et al. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer. 2011;11(1):60.
   PubMedGoogle Scholar
• Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer. 2016;122(24):3838–3847.
   PubMed Web of Science ®Google Scholar
• Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7(10):1116–1135.
   PubMed Web of Science ®Google Scholar
• Goeppert B, Folseraas T, Roessler S, et al. Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals therapeutic opportunities. Hepatology. 2020;72(4):1253–1266.
   PubMed Web of Science ®Google Scholar
• Cao J, Hu J, Liu S, et al. Intrahepatic cholangiocarcinoma: genomic heterogeneity between Eastern and Western patients. JCO Precis Oncol. 2020;4:557-569.
   Web of Science ®Google Scholar
• Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012;44(6):690–693.
   PubMed Web of Science ®Google Scholar
• Chan-On W, Nairismagi ML, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver flukerelated and non-infection-related bile duct cancers. Nat Genet. 2013;45(12):1474–1478.
   PubMed Web of Science ®Google Scholar
• Zou S, Li J, Zhou H, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun. 2014;5(1):5696.
   PubMed Web of Science ®Google Scholar
• Fujimoto A, Furuta M, Shiraishi Y, et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun. 2015;6(1):6120.
   PubMedGoogle Scholar
• Sabbatino F, Villani V, Yearley JH, et al. PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clin Cancer Res. 2016;22(2):470–478.
   PubMed Web of Science ®Google Scholar
• Ye Y, Zhou L, Xie X, et al. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion. J Surg Oncol. 2009;100(6):500–504.
   PubMed Web of Science ®Google Scholar
• Fontugne J, Augustin J, Pujals A, et al. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget. 2017;8(15):24644–24651.
   PubMedGoogle Scholar
• Gani F, Nagarajan N, Kim Y, et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2016;23(8):2610–2617.
   PubMed Web of Science ®Google Scholar
• Lim YJ, Koh J, Kim K, et al. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. Radiother Oncol. 2015;117(1):165–170.
   PubMed Web of Science ®Google Scholar
• Silva VWK, Askan G, Daniel TD, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin Clin Oncol. 2016;5(5):62.
   PubMed Web of Science ®Google Scholar
• Kunk PR, Obeid JM, Winters K, et al. Mismatch repair deficiency in cholangiocarcinoma. JCO. 2018;36(4_suppl):269.
   Web of Science ®Google Scholar
• Winkelmann R, Schneider M, Hartmann S, et al. Microsatellite instability occurs rarely in patients with cholangiocarcinoma: a retrospective study from a german tertiary care hospital. Int J Mol Sci. 2018;19(5):1421.
   PubMed Web of Science ®Google Scholar
• Weinberg BA, Xiu J, Lindberg MR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol. 2019;10(4):652–662.
   PubMed Web of Science ®Google Scholar
• Spizzo G, Puccini A, Xiu J, et al. Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open. 2020;5(3):e000682.
   PubMed Web of Science ®Google Scholar
• Ricci AD, Rizzo A, Brandi G. The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box? ESMO Open. 2020;5(e001042):e001042.
   PubMedGoogle Scholar
• Lin J, Shi J, Guo H, et al. Alterations in DNA damage repair genes in primary liver cancer. Clin Cancer Res. 2019;25(15):4701–4711.
   PubMed Web of Science ®Google Scholar
• Rovesti G, Leone F, Brandi G, et al. Prognostic role of a new index tested in European and Korean advanced biliary tract cancer patients: the PECS index. J Gastrointest Cancer. 2021;5.
   Google Scholar
• Neuzillet C, Casadei-Gardini A, Brieau B, et al. Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. Int J Cancer. 2020;147(11):3177–3188.
   PubMed Web of Science ®Google Scholar
• Salati M, Filippi R, Vivaldi C, et al. The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. Liver Int. 2020;40(3):704–711.
   PubMed Web of Science ®Google Scholar
• Vega-Benedetti AF, Loi E, Moi L, et al. Clustered protocadherins methylation alterations in cancer. Clin Epigenetics. 2019;11(1):100.
   PubMed Web of Science ®Google Scholar
• Massard C, Michiels S, Ferté C, et al. Highthroughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586–595.
   PubMed Web of Science ®Google Scholar
• Verlingue L, Malka D, Allorant A, et al. Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial. Eur J Cancer. 2017;87:2190–2198.
   PubMed Web of Science ®Google Scholar
• Neuzillet C, Casadei Gardini A, Brieau B, et al. Prediction of survival with second-line therapy in biliary tract cancer: actualisation of the AGEO CT2BIL cohort and European multicentre validations. Eur J Cancer. 2019;111:94–106.
   PubMed Web of Science ®Google Scholar
• Faloppi L, Del Prete M, Casadei Gardini A, et al. The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. Sci Rep. 2016;6(1):24136.
   PubMedGoogle Scholar
• Valle JW, Lamarca A, Goyal L, et al. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943–962.
   PubMed Web of Science ®Google Scholar
• Silverman IM, Murugesan K, Lihou CF, et al. Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma. J Clin Oncol. 2019;37(15_suppl):4080.
   Web of Science ®Google Scholar
• Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med. 2010;16(9):387–397.
   PubMed Web of Science ®Google Scholar
• Saha SK, Parachoniak CA, Ghanta KS, et al. Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. Nature. 2014;513(7516):110–114.
   PubMed Web of Science ®Google Scholar
• Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012;43(10):1552–1558.
   PubMed Web of Science ®Google Scholar
• Bhagavan NV, Ha CE. Essentials of medical biochemistry. 1st ed. Academic Press; 2011.
   Google Scholar
• Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013;32(25):3091–3100.
   PubMed Web of Science ®Google Scholar
• Mondesir J, Willekens C, Touat M, et al. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med. 2016;7:171–180.
   PubMed Web of Science ®Google Scholar
• Borger DR, Goyal L, Yau T, et al. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res. 2014;20(7):1884–1890.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45(12):1470–1473.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Borger DR, Kim Y, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014;21(12):3827–3834.
   PubMed Web of Science ®Google Scholar
• Goyal L, Govindan A, Sheth RA, et al. Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma. Oncologist. 2015;20(9):1019–1027.
   PubMed Web of Science ®Google Scholar
• Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019;10(4):751–765.
   PubMed Web of Science ®Google Scholar
• Kucukyurt S, Eskazan AE. New drugs approved for acute myeloid leukaemia in 2018. Br J Clin Pharmacol. 2019;85(12):2689–2693.
   PubMed Web of Science ®Google Scholar
• Lowery MA, Burris III HA, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(9):711–720.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Macarulla Mercade T, Javle M, et al. ClarIDHy: a global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs. placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Ann Oncol. 2019;30:851–934.
   Web of Science ®Google Scholar
• Harding JJ, Lowery MA, Shih AH, et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discov. 2018;8(12):1540–1547.
   PubMed Web of Science ®Google Scholar
• Delahousse J, Verlingue L, Broutin S, et al. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas. Eur J Cancer. 2018;90:83–91.
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Botman D, Smits MA, et al. Radioprotection of IDH1-mutated cancer cells by the IDH1-mutant inhibitor AGI-5198. Cancer Res. 2015;75(22):4790–4802.
   PubMed Web of Science ®Google Scholar
• Sulkowski PL, Corso CD, Robinson ND, et al. 2- Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017;9(375):2463.
   Web of Science ®Google Scholar
• Saha SK, Gordan JD, Kleinstiver BP, et al. Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov. 2016;6(7):727–739.
   PubMed Web of Science ®Google Scholar
• Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol. 2005;23(4):720–731.
   PubMed Web of Science ®Google Scholar
• Touat M, Ileana E, Postel-Vinay S, et al. Targeting FGFR signaling in cancer. Clin Cancer Res. 2015;21(12):2684–2694.
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signaling: from development to cancer. Nat Rev Cancer. 2010;10(2):116–129.
   PubMed Web of Science ®Google Scholar
• Helsten T, Elkin S, Arthur E, et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22(1):259–267.
   PubMed Web of Science ®Google Scholar
• Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–282.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, El-Rayes BF, Cotsoglou C, et al. ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations. J Clin Oncol. 2017;35(15_suppl):4017.
   Google Scholar
• Jain A, Borad MJ, Kelley RK, et al. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. JCO Precision Oncol. 2018;2:1–12.
   PubMed Web of Science ®Google Scholar
• Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014;45(8):1630–1638.
   PubMed Web of Science ®Google Scholar
• Santini D, Brandi G, Aprile G, et al. Bone metastases in biliary cancers: a multicenter retrospective survey. J Bone Oncol. 2018;12:33–37.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Maruki Y, Ueno M, et al. Frequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: a prospective observational study (PRELUDE study). Ann Oncol. 2019;30:723.
   Web of Science ®Google Scholar
• Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3(6):636–647.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ding X, Wang S, et al. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer Lett. 2016;380(1):163–173.
   PubMed Web of Science ®Google Scholar
• Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6(1):6087.
   PubMed Web of Science ®Google Scholar
• Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59(4):1427–1434.
   PubMed Web of Science ®Google Scholar
• Hall TG, Yu Y, Eathiraj S, et al. Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS ONE. 2016;11(9):e0162594.
   PubMed Web of Science ®Google Scholar
• Presta M, Chiodelli P, Giacomini A, et al. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 2017;179:171–187.
   PubMed Web of Science ®Google Scholar
• Hallinan N, Finn S, Cuffe S, et al. Targeting the fibroblast growth factor receptor family in cancer. Cancer Treat Rev. 2016;46:51–62.
   PubMed Web of Science ®Google Scholar
• Chae YK, Ranganath K, Hammerman PS, et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017;8(9):16052–16074.
   PubMedGoogle Scholar
• Park JO, Feng YH, Chen YY, et al. Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations. J Clin Oncol. 2017;37(15_suppl):4117.
   Web of Science ®Google Scholar
• Vogel A, Sahai V, Hollebecque A, et al. FIGHT-202: a phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA). Ann Oncol. 2019;30(LBA40):v876.
   Google Scholar
• Mazzaferro V, El-Rayes BF, Droz Dit BM, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120(2):165–171.
   PubMed Web of Science ®Google Scholar
• Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007;18(6):1637–1647.
   PubMed Web of Science ®Google Scholar
• Wohrle S, Henninger C, Bonny O, et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013;28(4):899–911.
   PubMed Web of Science ®Google Scholar
• Wohrle S, Bonny O, Beluch N, et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res. 2011;26(10):2486–2497.
   PubMed Web of Science ®Google Scholar
• Javle M, Kelley RK, Roychowdhury S, et al. Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Ann Oncol. 2018;29(viii720):viii720.
   PubMedGoogle Scholar
• Hollebecque A, Borad M, Sahai V, et al. Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations. Ann Oncol. 2018;29:viii205–70.
   Web of Science ®Google Scholar
• Goyal L, Saha SK, Liu LY, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion–positive cholangiocarcinoma. Cancer Discov. 2017;7(3):252–263.
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam BF, Arkenau H, Tran B, et al. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. Ann Oncol. 2018;29(mdy149):v100.
   PubMedGoogle Scholar
• Tran B, Meric-Bernstam F, Arkenau H, et al. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi’s. Ann Oncol. 2018;29:ix46–66.
   Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137.
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009;64(4):777–783.
   PubMed Web of Science ®Google Scholar
• Peck J, Wei L, Zalupski M, et al. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology. 2012;82(3):175–179.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Rankin C, Siegel AB, et al. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer. 2014;110(4):882–887.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Galdy S, Barriuso J, et al. The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. PLoS One. 2018;13(10):e0206007.
   PubMed Web of Science ®Google Scholar
• Javle MM, Hainsworth JD, Swanton C, et al. Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: preliminary data from MyPathway. J Clin Oncol. 2017;35(4_suppl):402.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554(7691):189–194.
   PubMed Web of Science ®Google Scholar
• Harding JJ, Cleary J, Shapiro G, et al. Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial. Ann Oncol. 2019;30:iv127.
   Web of Science ®Google Scholar
• Meric-Bernstam F, Hanna DL, El-Khoueiry AB, et al. Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): results from a phase I study. J clin oncol. 2021;39(3_suppl):299.
   Web of Science ®Google Scholar
• Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS ONE. 2014;9(12):e115383.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Ohnishi H, Ohtsuka K, et al. KRAS mutation as a potential prognostic biomarker of biliary tract cancers. Japan Clin Med. 2016; 7:33–39.
   PubMed Web of Science ®Google Scholar
• Cox AD, Fesik SW, Kimmelman AC, et al. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13(11):828–851.
   PubMed Web of Science ®Google Scholar
• Lai E, Liscia N, Donisi C, et al. Molecular-biology-driven treatment for metastatic colorectal cancer. Cancers (Basel). 2020;12(5):E1214.
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab T, Phelps MA, Li X, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29(17):2357–2363.
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Lopes A, Beare S, et al. A phase 1b study of selumetinib in combination with cisplatin and gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer. 2016;16(1):153.
   PubMed Web of Science ®Google Scholar
• Lowery MA, Bradley M, Chou JF, et al. Binimetinib plus gemcitabine and cisplatin phase I/II trial in patients with advanced biliary cancers. Clin Cancer Res. 2019;25(3):937–945.
   PubMed Web of Science ®Google Scholar
• Shroff RT, Yarchoan M, O’Connor A, et al. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer. 2017;116(11):1402–1407.
   PubMed Web of Science ®Google Scholar
• Casadei Gardini A, Santini D, Aprile G, et al. Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. Oncotarget. 2017;8(39):66699–66708.
   PubMedGoogle Scholar
• El-Khoueiry AB, Rankin CJ, Ben-Josef E, et al. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012;30(4):1646–1651.
   PubMed Web of Science ®Google Scholar
• Moehler M, Maderer A, Schimanski C, et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. Eur J Cancer. 2014;50(18):3125–3135.
   PubMed Web of Science ®Google Scholar
• Giampieri R, Ziranu P, Daniele B, et al. From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): circulating predictive biomarkers to anti-VEGFR therapy. Cancers (Basel). 2020;12(5):1330.
   Web of Science ®Google Scholar
• O’Rourke CJ, Munoz-Garrido P, Andersen JB. Molecular targets in cholangiocarcinoma. Hepatology. 2021;73(Suppl 1):62–74.
   PubMedGoogle Scholar
• Lamarca A, Barriuso J, McNamara MG, et al. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol. 2020;73(1):170–185.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Blay J-Y, Chau I, et al. VE-BASKET, a first-in-kind, phase II, histology-independent “basket” study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). J Clin Oncol. 2014;32(15_suppl): 2533-2533. DOI:https://doi.org/10.1200/jco.2014.32.15_suppl.2533.
   Google Scholar
• Wainberg ZA, Lassen UN, Elez E, et al. Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial. J Clin Oncol. 2019;37(4_suppl):187.
   Web of Science ®Google Scholar
• Shinada K, Tsukiyama T, Sho T, et al. RNF43 interacts with NEDL1 and regulates p53-mediated transcription. Biochem Biophys Res Commun. 2011;404(1):143–147.
   PubMed Web of Science ®Google Scholar
• Loregger A, Grandl M, Mejias-Luque R, et al. The E3 ligase RNF43 inhibits Wnt signaling downstream of mutated beta-catenin by sequestering TCF4 to the nuclear membrane. Sci Signal. 2015;8(393):ra90.
   PubMed Web of Science ®Google Scholar
• Koo BK, Van Es JH, van den Born M, et al. Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia. Proc Natl Acad Sci. 2015;112(24):7548–7550.
   PubMed Web of Science ®Google Scholar
• Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2):e000023.
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Ou SI, et al. Safety and antitumor activity of the multi-targeted pan-TRK, ROS1, and ALK inhibitor entrectinib (RXDX-101): combined results from two phase 1 trials (ALKA-372 001 and STARTRK-1). Cancer Discov. 2007;7(4):400–409.
   Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014;19(3):235–242.
   PubMed Web of Science ®Google Scholar
• Gu TL, Deng X, Huang F, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One. 2011;6:e15640.
   PubMed Web of Science ®Google Scholar
• Ruzzenente A, Fassan M, Conci S, et al. Cholangiocarcinoma heterogeneity revealed by Multigene mutational profiling: clinical and prognostic relevance in surgically resected patients. Ann Surg Oncol. 2016;23(5):1699–1707.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365.
   PubMed Web of Science ®Google Scholar
• Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147(8):2190–2198.
   PubMed Web of Science ®Google Scholar
• Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 2020;6(6):888–894.
   PubMed Web of Science ®Google Scholar
• Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a nonrandomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(8):611–621.
   PubMed Web of Science ®Google Scholar
• Ioka T, Ueno M, Oh DY, et al. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). J Clin Oncol. 2019;37(4_suppl):387.
   Web of Science ®Google Scholar
• Teicher BA. TGFβ-directed therapeutics: 2020. Pharmacol Ther. 2020;21:107666.
   Google Scholar
• Yoo C, Oh DY, Choi HJ, et al. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer. J Immunother Cancer. 2020;8(1):e000564.
   PubMed Web of Science ®Google Scholar
• Minchom A, Aversa C, Lopez J. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther Adv Med Oncol. 2018;10:1758835918786658.
   Web of Science ®Google Scholar
• Lamarca A, Barriuso J, McNamara MG, et al. Biliary tract cancer: state of the art and potential role of DNA damage repair. Cancer Treat Rev. 2018;70:168–177.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Mollica V, Cimadamore A, et al. Is there a role for immunotherapy in prostate cancer? Cells. 2020;9(9):E2051.
   PubMed Web of Science ®Google Scholar
• Arora S, Velichinskii R, Lesh RW, et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors. Adv Ther. 2019;36(10):2638–2678.
   PubMed Web of Science ®Google Scholar
• Reisländer T, Groelly FJ, Tarsounas M. DNA damage and cancer immunotherapy: a STING in the tale. Mol Cell. 2020;80(1):21–28.
   PubMed Web of Science ®Google Scholar
• Ricci AD, Rizzo A, Brandi G. Immunotherapy in biliary tract cancer: worthy of a second look. Cancer Control. 2020;27(3):1073274820948047.
   Web of Science ®Google Scholar
• Mouw KW, Goldberg MS, Konstantinopoulos PA, et al. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7(7):675–693.
   PubMed Web of Science ®Google Scholar
• La Nasa G, Caocci G, Morelli E, et al. Health related quality of life in patients with onco-hematological diseases. Clin Pract Epidemiol Ment Health. 2020;16(1):174–179.
   PubMedGoogle Scholar